Jim Simons
ADCT icon

Jim Simons’s ADC Therapeutics ADCT Stock Holding History

Jim Simons’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.12M Buy
+299,278
New +$1.18M ﹤0.01% 2211
2022
Q4 		– Sell
-71,100
Closed -$343K – 4078
2022
Q3 		$343K Sell
71,100
-8,800
-11% -$63.7K ﹤0.01% 3141
2022
Q2 		$635K Buy
+79,900
New +$756K ﹤0.01% 3008

Other funds holding ADCT

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Jim Simons's ADCT Position: Q1 2026 in Review

Jim Simons opened a new position in ADC Therapeutics (ADCT) in Q1 2026: 299,278 shares worth $1.12M. The stake represents ﹤0.01% of the portfolio and ranks #2211 among its holdings. This is a return to the name: Jim Simons previously reported a position in ADCT as recently as Q3 2022.

Jim Simons first reported a position in ADCT in Q2 2022 and has held it in 3 quarters since. 118 funds tracked by Wall St. Rank hold ADCT as of Q1 2026.

  • Jim Simons held 299,278 shares of ADC Therapeutics worth $1.12M as of Q1 2026.
  • ADC Therapeutics was a new Jim Simons position in Q1 2026.
  • ADC Therapeutics made up ﹤0.01% of Jim Simons's portfolio in Q1 2026, its #2211 holding.
  • Jim Simons first reported a position in ADC Therapeutics in Q2 2022 and has held it in 3 quarters since.
  • 118 funds tracked by Wall St. Rank held ADC Therapeutics as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.